Point72 Asia (Singapore) Pte. Ltd. Theravance Biopharma, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $646 Billion
- Q3 2025
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 2 shares of TBPH stock, worth $34. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2
Previous 2,330
99.91%
Holding current value
$34
Previous $25.7 Million
99.91%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding TBPH
# of Institutions
170Shares Held
50.5MCall Options Held
36.5KPut Options Held
147K-
Madison Avenue Partners, LP New York, NY9.51MShares$165 Million12.7% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$130 Million2.09% of portfolio
-
Newtyn Management, LLC New York, NY4.95MShares$86.1 Million12.08% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$65.7 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$48 Million4.22% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $1.16B
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...